2seventy bio, Inc.

5.51 USD
-0.45 (-7.55%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

2seventy bio, Inc. stock is up 37.41% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Feb 18:33 20 Sep, 2024 10.00 CALL 378 4

About 2seventy bio, Inc.

2seventy bio, Inc. focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

  • Leerink Partners
    Wed Jan 31, 07:28
  • TD Cowen
    Wed Jan 31, 05:26